Loading clinical trials...

COMPLETEDPHASE2

Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies

Allogeneic Hematopoietic Cell Transplantation Using a Non-Myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Older Patients With Hematologic Malignancies

NCT00185640•Stanford University

View on ClinicalTrials.gov

Summary

To measure how frequently and to what degree a complication of transplant cell acute graft versus host disease (GvHD) occurs.

Detailed Description

This study evaluated whether TLI-ATG conditioning followed by allogeneic hematpoietic cell transplant (HCT), which has provided excellent overall survival for patients with relapsed lymphoma after failed autologous HCT, provides a similar benefit in the setting of elderly patients with hematologic malignancies.

Eligibility

Age

50 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Any patient with one of the following hematolymphoid malignancies or syndromes in whom allogeneic hematopoietic stem cell transplant (HST) is warranted. Specific disease categories include:
•* Indolent advanced stage non-Hodgkin lymphomas
•* Mantle cell lymphoma
•* Chronic lymphocytic leukemia
•* Hodgkin disease (Hodgkin's lymphoma)
•* Acute leukemias in complete remission
•* Aplastic anemia
•* Paroxysmal nocturnal hemoglobinuria
•* Myelodysplastic or myeloproliferative syndromes.
•* Other selected malignancies/disorders may also be considered but must be approved by the transplant team and the Principal Investigator.
+3 more criteria

Exclusion Criteria

•Progressive hematolymphoid malignancies despite conventional therapies, or acute leukemias not in complete remission.
•Uncontrolled central nervous system (CNS) involvement with disease
•Fertile men or women unwilling to use contraceptive techniques during and for 12 months following treatment
•Pregnant
•Cardiac ejection fraction \< 30%
•Uncontrolled cardiac failure
•Pulmonary diffusing capacity (DLCO) \< 40% predicted
•Elevation of bilirubin to \> 3 mg/dL
•Transaminases \> 4 x the upper limit of normal
•Creatinine clearance \< 50 cc/min (24-hour urine collection)
+5 more criteria

Locations (1)

Stanford University School of Medicine

Stanford, California, United States

Key Dates

Start Date

March 1, 2003

Primary Completion Date

April 1, 2014

Completion Date

January 1, 2016

Last Updated

June 29, 2021

Enrollment

303

ACTUAL participants

Conditions

Blood CancerLeukemia

Interventions

Cyclosporine

DRUG

Anti-thymocyte globulin (ATG)

DRUG

Mycophenolate mofetil (MMF)

DRUG

Filgrastim

DRUG

Total Lymphoid Irradiation (TLI)

RADIATION

Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants

NCT00106925

Graft-versus-leukemiaGraft vs Host Disease+1 more

View study

RECRUITINGPHASE1

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

NCT07388563

Lymphoma, T Cell, PeripheralT-cell Lymphoma+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 29, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies

Inclusion Criteria

Exclusion Criteria

Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

Phase I Study of HC-7366 for Acute Myeloid Leukemia

Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients

VAC Regimen for AML Patients Who Failed to Response to VA Regimen